Int. J. Mol. Sci., 2023 · DOI: 10.3390/ijms24098135 · Published: May 2, 2023
Traumatic spinal cord injury (SCI) leads to neuroinflammation and hinders nerve regeneration, often causing permanent issues. Current treatments offer limited functional improvements. New strategies are needed to address inflammation and stimulate the body's own repair mechanisms to improve outcomes for SCI patients. Cyclic adenosine monophosphate (cAMP) is a key molecule in the central nervous system that regulates these processes, and increasing cAMP levels has shown promise in experimental models.
cAMP-specific PDEs offer a promising target for developing new therapies for SCI by modulating neuroinflammation and promoting neuroregeneration.
Combining cAMP-specific PDE inhibitors with other treatments, such as cell transplantation, may enhance functional recovery after SCI.
Developing subtype-specific PDE inhibitors can minimize side effects and improve the efficacy of SCI treatment.